Evaluation of 177Lu-DOTA-sst 2 antagonist versus 177Lu-DOTA-sst 2 agonist binding in human cancers in vitro

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1886-1890

  Cescato, Renzo ^a   Waser, Beatrice ^a   Fani, Melpomeni ^b   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cancer targeting; DOTA sst 2 antagonist; DOTA sst 2agonist; Receptor autoradiography; Somatostatin receptors

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; DOTA BASS LU 177; DOTATATE LU 177; LUTETIUM 177; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN 28; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; LIGAND; LUTETIUM; OLIGOPEPTIDE; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS; SOMATOSTATIN RECEPTOR 2; TETRAXETAN;

ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BREAST CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM CANCER; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; AMINO ACID SEQUENCE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN BINDING;

AMINO ACID SEQUENCE; AUTORADIOGRAPHY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LIGANDS; LUTETIUM; NEOPLASMS; OLIGOPEPTIDES; PROTEIN BINDING; RADIOISOTOPES; RECEPTORS, SOMATOSTATIN;

EID: 83755161916     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095778     Document Type: Article

References (28)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427. (Pubitemid 37056239)
2. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
3. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247. (Pubitemid 43817847)
4. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735-1738.
5. Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011;52:841-844.
6. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
7. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610-616. (Pubitemid 34507110)
8. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
9. Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3 and sst5 receptors: Effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502-511. (Pubitemid 46768493)
10. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936-941.
11. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441. (Pubitemid 44715214)
12. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326.
13. Reubi JC, Waser B, Khosla S, et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 1992;74:1082-1089.
14. Reubi JC, Waser B, van Hagen M, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992;50:895-900.
15. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res. 1992;52:6074-6078.
16. Reubi JC, Gugger M, Waser B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-862. (Pubitemid 34671290)
17. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793. (Pubitemid 36612963)
18. Fani M, Mueller A, Tamma ML, et al. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. J Nucl Med. 2010;51:1771-1779.
19. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
20. Cescato R, Erchegyi J, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem. 2008;51:4030-4037. (Pubitemid 351956530)
21. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969-5977. (Pubitemid 20331408)
22. Erchegyi J, Cescato R, Grace CR, et al. Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. J Med Chem. 2009;52:2733-2746.
23. Decristoforo C, Zaknun J, Kohler B, Oberladstaetter M, Riccabona G. The use of electronic autoradiography in radiopharmacy. Nucl Med Biol. 1997;24:361-365. (Pubitemid 27294680)
24. 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865-873.
25. Papotti M, Macri L, Bussolati G, Reubi JC. Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer. 1989;43:365-369. (Pubitemid 19092312)
26. Albérini JL, Meunier B, Denzler B, et al. Somatostatin receptor in breast cancer and axillary nodes: Study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat. 2000;61:21-32. (Pubitemid 30440547)
27. Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol. 1993;83:75-79. (Pubitemid 23030175)
28. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is clinically feasible. J Nucl Med. 2011;52:1412-1417.